Tretten FDA Approval History
Last updated by Judith Stewart, BPharm on June 22, 2020.
FDA Approved: Yes (First approved December 23, 2013)
Brand name: Tretten
Generic name: coagulation factor XIII A-subunit (recombinant)
Company: Novo Nordisk
Treatment for: Factor XIII A-Subunit Deficiency
Tretten (coagulation factor XIII A-subunit (recombinant)) is a recombinant analogue of the human Factor XIII A-subunit for the prevention of bleeding in patients who have the rare clotting disorder congenital Factor XIII A-subunit deficiency.
Development timeline for Tretten
| Date | Article |
|---|---|
| Dec 23, 2013 | Approval FDA Approves Tretten to Treat Rare Genetic Clotting Disorder |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
